These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 33881447)

  • 1. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
    Trum NA; Zain J; Martinez XU; Parekh V; Afkhami M; Abdulla F; Carson KR; Rosen ST; Bennett CL; Querfeld C
    Br J Dermatol; 2022 Jan; 186(1):153-166. PubMed ID: 34427917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic Characterization of Mogamulizumab-associated Rash.
    Wang JY; Hirotsu KE; Neal TM; Raghavan SS; Kwong BY; Khodadoust MS; Brown RA; Novoa RA; Kim YH; Rieger KE
    Am J Surg Pathol; 2020 Dec; 44(12):1666-1676. PubMed ID: 32976123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
    Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.
    Mitsunaga K; Bagot M; Ram-Wolff C; Guenova E; von Gugelberg C; Hodak E; Amitay-Laish I; Papadavid E; Jonak C; Porkert S; Scarisbrick J; Applewaite R; Beylot-Barry M; Nicolay J; Quaglino P; Sanches JA; Cury-Martins J; Lora-Pablos D; Ortiz P
    Br J Dermatol; 2024 Aug; 191(3):419-427. PubMed ID: 38596857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
    Muszbek N; Remak E; Xin Q; McNamara L; Jones T
    J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
    Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
    Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
    L'Orphelin JM
    Ther Adv Hematol; 2024; 15():20406207241235777. PubMed ID: 38456078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
    Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
    J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
    [No Abstract]   [Full Text] [Related]  

  • 20. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
    Musiek ACM; Rieger KE; Bagot M; Choi JN; Fisher DC; Guitart J; Haun PL; Horwitz SM; Huen AO; Kwong BY; Lacouture ME; Noor SJ; Rook AH; Seminario-Vidal L; Vermeer MH; Kim YH
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):29-40. PubMed ID: 34816383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.